KRAS and lung adenocarcinoma: Moreover, this mutant KRAS signature was significantly positively enriched in KRAS- versus EGFR (epidermal growth factor receptor)-mutant LUAD (lung adenocarcinoma; GSE43458) from the BATTLE trial [25,26] (Figure 4f).